|Year : 2018 | Volume
| Issue : 3 | Page : 270-284
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Tracy King1, Jacqueline Jagger2, Jodie Wood3, Carmel Woodrow4, Alicia Snowden5, Sally Haines6, Christina Crosbie7, Kristen Houdyk8
1 Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia
2 Cancer Services, Gosford Hospital, Gosford, NSW, Australia
3 Cancer Services, Flinders Medical Centre, Adelaide, SA, Australia
4 Division of Cancer Services, Princess Alexandra Hospital, Brisbane, QLD, Australia
5 Precision Haematology, Melbourne, Australia
6 Haematology and Stem Cell Transplantation Service, The Alfred Hospital, Melbourne, Australia
7 Haematology, St. Charles Gairdner Hospital, Nedlands WA, Australia
8 Cancer Clinical Trials Centre, Austin Health, Melbourne, VIC, Australia
|Date of Submission||27-Feb-2018|
|Date of Acceptance||07-Mar-2018|
|Date of Web Publication||31-May-2018|
Institute of Haematology, Royal Prince Alfred Hospital, Sydney
Source of Support: None, Conflict of Interest: None
Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment toxicities. Daratumumab is a monoclonal antibody approved for the treatment of MM in the relapsed/refractory setting. Clinical studies found that daratumumab showed good tolerability as a monotherapy and in combination with current standard therapies. However, the administration of daratumumab does require specific management considerations. It is administered as an intravenous infusion and infusion-related reactions (IRRs) may occur. Daratumumab also interferes with routine blood transfusion tests, giving false positives for the indirect antiglobulin test. This article highlights key nursing care considerations and practical management aspects to improve the treatment experience of patients receiving daratumumab infusions. Pretreatment aspects, patient education, pre- and post-medication, daratumumab administration, and the management of IRRs are discussed. An IRR management sheet that could be used by nurses and a patient information sheet are located at the end of this article.
Keywords: Daratumumab, infusion-related reaction, multiple myeloma
|How to cite this article:|
King T, Jagger J, Wood J, Woodrow C, Snowden A, Haines S, Crosbie C, Houdyk K. Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. Asia Pac J Oncol Nurs 2018;5:270-84
|How to cite this URL:|
King T, Jagger J, Wood J, Woodrow C, Snowden A, Haines S, Crosbie C, Houdyk K. Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. Asia Pac J Oncol Nurs [serial online] 2018 [cited 2020 Oct 22];5:270-84. Available from: https://www.apjon.org/text.asp?2018/5/3/270/229879
| Introduction|| |
Multiple myeloma (MM) is a malignant disorder of the plasma cells that often leads to damage and weakening of the bone, compromised immunity, cytopenia, and damage to the kidneys and other organs. It is the second-most common hematologic malignancy and accounts for as many as 2% of deaths from all cancers. In Australia, in 2013, the age-adjusted incidence for MM was 6.3/100,000 with 1,637 cases diagnosed. The incidence of MM is higher among men than among women and predominately affects patients aged 65 years or older. While MM remains an incurable cancer, life expectancy has improved significantly due to routine use of new targeted therapies., In Australia, there has been at least a 21% increase in the 5-year overall survival (OS) rate from the years 1984–1988 to 2009–2013.
The advanced age of the majority of patients with MM often means that patients present with significant coexisting medical conditions, such as renal impairment, diabetes, and pulmonary and cardiac diseases that may adversely impact outcomes. Management of these comorbidities plays a key role in optimizing the efficacy of treatment. Furthermore, for patients to benefit from improved OS, they are required to adhere to increasing lines of multi-agent therapy over longer periods of time. Most patients have had several lines of therapy and experience disease-related effects alongside associated treatment toxicities, such as cytopenia, infection, thromboembolism, peripheral neuropathy, gastrointestinal effects, and even second primary malignancies.,
The diagnosis of a chronic cancer such as MM with the resultant disease and treatment-related effects has an adverse impact on a patient's health-related quality of life (HRQoL).,,,, Health professionals caring for those with MM should be mindful of the chronic and complex nature of MM, and the individual impact on each patient, when optimizing treatment delivery and best supportive care. The goals of therapy remain to control the disease, maximize the patient's HRQoL, and prolong survival.
The incorporation of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) into the standard of care is currently one of the most effective approaches for patients with newly diagnosed MM. As there is no curative treatment, MM inevitably relapses and several lines of therapy are typically required. For patients who are refractory to PI and IMiD drugs, the prognosis can be poor with a median OS of only 9 months. Drugs currently approved for use in Australia for the treatment of MM are outlined in [Table 1].
|Table 1: Commonly used drugs currently approved for use in Australia for the treatment of multiple myeloma|
Click here to view
Novel agents such as daratumumab have recently been approved for use in the relapsed/refractory (RR) setting. Daratumumab is a human IgGκ monoclonal antibody that targets CD38, which is highly expressed on myeloma cells. Daratumumab has direct and indirect antitumor activity and diverse mechanisms of action including induction of apoptosis, immune-mediated actions, and immunomodulatory functions. In heavily pretreated patients with relapsed or RR MM, single-agent daratumumab was associated with an overall response rate of 31% and a medial OS of 20.1 months.
Clinical trials evaluating the combination of daratumumab with PIs and IMiDs in patients with relapsed or RR MM demonstrated that adding daratumumab improved progression-free survival (PFS) while maintaining an acceptable safety profile. The CASTOR phase III clinical trial randomized 498 patients who had received a median of two prior lines of therapy to daratumumab therapy in combination with bortezomib and dexamethasone or bortezomib and dexamethasone alone. Addition of daratumumab resulted in significant improvement in PFS compared to bortezomib and dexamethasone alone at a prespecified interim analysis. After a median follow-up period of 7.4 months, the median PFS was not reached in the daratumumab group (95% confidence interval [CI]: 12.3 to could not be estimated) and was 7.2 months (95% CI: 6.2–7.9 months) in the control group. The hazard ratio (HR) for progression or death for daratumumab versus control was 0.39 (95% CI: 0.28–0.53, P< 0.001), crossing the prespecified stopping boundary. Based on the results of the interim analysis, the Independent Data and Safety Monitoring Committee recommended that the trial be unblinded early. Additional PFS data have been published recently and, after a median follow-up of 19.4 months, the median PFS for the daratumumab group was 16.7 months compared to 7.1 months in the control group (HR: 0.31, 95% CI: 0.24–0.39).
The POLLUX phase III clinical trial randomized 569 patients who had received a median of one prior line of therapy to daratumumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone. At a median follow-up of 13.5 months in a prespecified interim analysis, the median PFS for the daratumumab group was not reached (95% CI: could not be estimated) as compared with 18.4 months (95% CI: 13.9 to could not be estimated) in the control group. The HR for disease progression or death in the daratumumab group versus the control group was 0.37 (95% CI: 0.27–0.52, P < 0.001). More recent data showed that after a median follow-up of 25.4 months, PFS was significantly prolonged with the daratumumab group compared to the control group (not reached versus 17.5 months, HR: 0.41, 95% CI: 0.31–0.53, P < 0.0001).
Daratumumab was approved for use by the Food and Drug Administration in the United States in 2015 and by the Therapeutic Goods Administration in Australia in 2017. In Australia, it is indicated as a monotherapy for the treatment of patients with MM who have received at least three prior lines of therapy including a PI and an IMiD or who are refractory to both a PI and an IMiD. Daratumumab is also approved for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy. The cost of daratumumab therapy is currently not subsidized by the Australian government through the Pharmaceutical Benefits Scheme (PBS). This would normally preclude a drug from becoming “standard of care” until such a time that successful PBS listing has been granted.
Clinical studies found that daratumumab showed good tolerability as a monotherapy and in combination with current standard therapies. However, the administration of daratumumab does require specific management considerations. Daratumumab is delivered as an intravenous (IV) infusion, and infusion-related reactions (IRRs), common to all monoclonal antibodies (mAbs), may occur. Most infusion reactions related to mAbs are caused by cytokine release. The symptoms are generally mild to moderate in severity and usually occur within the first couple of hours, most often with the first infusion, and the symptoms appear to subside with each subsequent dose. Cytokine release reactions may be managed by short-term cessation of the monoclonal antibody infusion, with supportive measures such as administration of oxygen, corticosteroids, bronchodilators and histamine blockers, and restarting the infusion at a slower rate. Anaphylactic reactions to mAbs are rare but are reported occasionally. Differentiation of a cytokine release syndrome from anaphylactic reaction can be difficult to determine in the early stages. A true anaphylactic reaction usually has a rapid onset within the first few minutes of infusion. Cytokine release reactions are more commonly within 30–120 min of infusion. Initial management of an anaphylactic reaction is the same as an IRR resulting from cytokine release reactions. Accurate documentation of the onset of symptoms is vital to assist in diagnosis. An anaphylactic reaction is more likely to have respiratory symptoms, hypotension, and/or cutaneous symptoms and will require early administration of epinephrine to avoid clinical deterioration.
IRRs were reported in approximately half of all patients treated with daratumumab, with most occurring during the first infusion. The occurrence of IRRs can be influenced by the infusion rate  and the median time to onset of a reaction was 1.4 h. In clinical trials (monotherapy and combination treatments; n = 820), 46% of patients experienced IRRs with the first infusion, 2% with the second infusion, and 3% with subsequent infusions. The incidence of infusion interruptions was 42%. Less than 1% of patients had a Grade 3 infusion reaction with second or subsequent infusions. No Grade 4 or 5 infusion reactions occurred [Table 2] for definition of IRR grades]. The IRRs seen were generally mild and discontinuations due to IRRs were rare. In clinical trials of daratumumab monotherapy, no discontinuations or life-threatening IRRs were observed. In combination studies, only five patients (0.8%) discontinued daratumumab treatment due to IRRs. There was a lower incidence of IRRs (27.7%) in the ALCYONE trial, which randomized 706 patients with newly diagnosed MM to bortezomib, melphalan, and prednisone alone or with daratumumab. The reason for the lower incidence of IRRs in this study is not clear.
|Table 2: Grading of infusion-related reactions according to the National Cancer Institute common terminology criteria for adverse events|
Click here to view
Daratumumab IRRs are characterized by nasal congestion, throat irritation, cough, as well as chills, vomiting, and nausea. Severe (grade 3) IRRs included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension.
In addition to IRRs, the most commonly reported adverse effects (AEs) (≥20%) are fatigue, nausea, back pain, anemia, neutropenia, and thrombocytopenia. [Table 3] lists adverse reactions that occurred at a rate of ≥10% for patients treated with daratumumab monotherapy during three open-label clinical studies. When daratumumab is used in combination with other active MM agents, then the adverse reaction profile can change. Common adverse reactions for combination therapies during clinical studies were thrombocytopenia for daratumumab with bortezomib and neutropenia for daratumumab with lenalidomide. Diarrhea was also common with both regimens.
|Table 3: Adverse reactions in multiple myeloma patients treated with daratumumab monotherapy (16 mg/kg)|
Click here to view
Another important aspect of daratumumab administration is the interference of daratumumab with routine blood transfusion laboratory tests. Daratumumab does not interfere with ABO/RhD typing, but does give false-positive results for the indirect antiglobulin test (IAT; Coombs test), which is used for the detection of irregular blood group antibodies., As a result, it is important that blood typing is done prior to administration of daratumumab and that health-care providers, pathology departments, and blood banks are aware that the patient is receiving daratumumab therapy. Patients should be supplied with an identification card providing their blood type and explaining that they are receiving daratumumab.
Daratumumab can also affect the determination of complete response and disease progression in some patients with IgG kappa myeloma protein. This is because daratumumab is a human IgG kappa monoclonal antibody that can be detected on the serum protein electrophoresis and immunofixation assays used for the clinical monitoring of endogenous monoclonal immunoglobulins (M-protein), leading to false-positive assay results.,
Current standard therapies for MM (PIs, IMiDs, corticosteroids, and alkylating agents) use multiple administration modalities. For example, bortezomib (PI) can be administered intravenously but, more commonly, subcutaneously, and lenalidomide (IMID) is administered orally. A trained health professional must deliver all daratumumab infusions. Based on experience from clinical trials, the median duration of the first infusion is 7 h (minimum 6.5 h). This does not include premedication or monitoring times and it will take longer if the patient experiences IRRs. As a result, it is important to provide relevant information about daratumumab treatment to patients. This should include its route of administration, hospital visits required, and concomitant medications, so patient expectations can be managed around the schedule of treatment and potential associated IRRs. This article outlines some key nursing care considerations and practical management aspects to help prevent and successfully manage IRRs and to improve the treatment experience of patients receiving daratumumab infusions.
| Daratumumab Administration|| |
The following nursing considerations and practical approaches are based on clinical experience gained from a variety of centers across Australia in the public and private sectors and the recommendations for daratumumab administration from the pharmaceutical manufacturer (Janssen-Cilag). A checklist outlining the key aspects of daratumumab administration is given in [Figure 1].
|Figure 1: Checklist for nurses for the preparation and administration of daratumumab|
Click here to view
Patient preassessment (up to 2 weeks prior to starting treatment)
There are a range of patient assessments that need to be performed before starting treatment with daratumumab. Patients should be assessed 1–2 weeks prior to treatment for the following:
Vein assessment for peripheral intravenous cannula
Daratumumab is administered as an IV infusion; therefore, it is important to establish that the patient has suitable IV access for frequent insertions of peripheral IV cannulas (PIVCs) and subsequent infusions. If PIVC is not feasible, then alternative venous access will be required. Alternative access devices may include a central venous access device such as a peripherally inserted central catheter, implantable venous port, or tunneled or nontunneled central venous catheter.
History of respiratory diseases
Special care needs to be taken for patients with chronic obstructive pulmonary disease (COPD) or chronic asthma. Forced expiratory volume in 1 s (FEV1) testing may be required in patients if COPD is suspected. Patients who use inhaled bronchodilators for mild asthma should be advised to bring inhalers with them for the first infusion. For patients with a history of COPD or severe persistent asthma, post-infusion medications such as antihistamines, short- and long-acting bronchodilators, and inhaled corticosteroids should be considered.
Daratumumab is prescribed by patient's body weight; an accurate baseline weight must be recorded. Weight measurements should be made before each infusion administration and the dose of daratumumab adjusted if there is a 10% change from baseline weight or in accordance with institutional guidelines.
Patients should be assessed 1–3 days prior to treatment for the following
Pre-existing conditions and comorbidities
Daratumumab is currently approved for use in Australia in patients with relapsed or refractory MM. Therefore, establishing pre-existing disease or treatment-related side effects prior to commencement of daratumumab therapy will ensure accurate assessment of new symptoms or worsening pre-existing symptoms. Common disease or treatment effects may include peripheral neuropathy, cytopenia, thrombotic events, gastrointestinal effects, and other comorbidities of older age such as cardiac or respiratory disease or diabetes.
Daratumumab gives false-positive results for the IAT; Coombs test. Patients should obtain a baseline red blood cell phenotype 1–3 days prior to starting daratumumab therapy so that blood provided for transfusion is of the correct phenotype. Genotyping may be considered if phenotyping is not possible due to recent transfusion, or if the patient has a positive direct antiglobulin test, or if suitable phenotyping reagents are not available. Patients should be supplied with a transfusion card to indicate that they are receiving daratumumab and carry this card throughout the treatment period and for at least 6 months after the treatment ends., The card should also specify the blood profile (ABO, Rh, and IAT) determined before the first infusion of daratumumab, along with information for health-care providers and blood transfusion departments about the interference of daratumumab with the IAT test. Alternatively, the patient could wear a medic alert bracelet. Patient records should also include an alert that daratumumab treatment may result in a false-positive IAT.
Patient education (1–3 days prior to starting treatment)
Health-related information promotes self-care, informs treatment decisions, and improves effectiveness of clinical care., The treating team need to ensure that they give the patient and their family the relevant information and opportunity to ask questions about daratumumab, including treatment schedule and likely duration, AEs, and infusion reactions. Patients should be provided with written information to support their learning and understanding. These could be in the form of local information fact sheets, or those provided by third parties such as patient advocacy groups or NPS Medicine Wise or the manufacturer. There is a page at the end of this article that lists key information about the administration of daratumumab that could be given to patients. Patients and their families, where possible, should be provided with time and support to process and understand the information provided, to ask questions, and to facilitate an informed decision. There are various aspects of daratumumab treatment outlined below that need to be explained to the patient.
Duration and frequency of treatment
It is important that the sequencing and duration of the treatment is explained. Many patients will have had previous MM treatments that have been administered orally, intravenously, or subcutaneously and need to be made aware of the relatively long infusion time for daratumumab, particularly for the first infusion. Daratumumab monotherapy is administered weekly during the first 8 weeks, every 2 weeks for the following 16 weeks, and monthly thereafter [Figure 2]. The first infusion has a median duration of 7 h, with a median duration of second and subsequent infusions of 4.3 and 3.5 h, respectively. This infusion time does not include the time required for premedications or first dose post-infusion monitoring, and the infusion may take longer if there are IRRs. Suggest that the patient brings something to keep them entertained during the infusion time, for example, a book or some music. Having a support person to help with transport to and from the hospital, especially if lengthy infusions are required, can help cut down on associated parking costs.
|Figure 2: Dosing schedule for daratumumab monotherapy. On daratumumab infusion days, 20 mg of dexamethasone is given as a pre-infusion medication|
Click here to view
After the first infusion, it is recommended that the patient waits for 2 h in the unit so that they can be observed for IRRs before they are discharged from the hospital. Ensure that the patient understands that they may need to be admitted to hospital to complete the infusion if an IRR occurs and should be advised to bring an overnight bag with necessities.
Patients should be reassured that most IRRs are mild in severity and are manageable. The importance of pre- and post-medications for controlling and limiting IRRs should be explained and written information should be provided on when and how to use them. Check that the patient has a “toolbox” at home for management of IRRs that should include supportive medications such as antinausea tablets, antidiarrheal, antacid/proton pump inhibitors, and thermometer etc. and understands how to contact the treatment center in and out of hours should they experience difficulty.
Patients receiving combination therapy should also be given information about the additional medication. Provide patients with written medication schedules, especially if they are receiving daratumumab in combination with other concomitant supportive medication.
Explain why blood typing is required prior to daratumumab administration and check that the patient has a blood type wallet card or medic alert bracelet. Explain that this should be carried by the patient for up to 6 months after daratumumab treatment is completed.
Supportive care and patient consent form
Explain to the patient that some of the pre-medications, and daratumumab itself, may cause drowsiness and it is recommended for the first cycle (4 weeks) of treatment that someone brings them to and collects them from the hospital on the day of treatment. Ensure that there are appropriate post-infusion care and support arrangements in place. Ensure that the patient has completed patient consent forms in accordance with local policy, and a patient assessment questionnaire, as per local assessment practice, for example, pre-treatment symptom assessment, HRQoL, or other patient-reported outcome measures (PROMs).
Scheduling and capacity management for treatment centers (1–2 weeks prior to starting treatment)
The first administration of daratumumab can take as long as 10 h (including pre-medication and post-infusion monitoring); therefore, it is necessary to establish if this can be supported in the day unit. The treatment time may be longer than 10 h if there are IRRs. It is recommended that an inpatient bed as well as an outpatient hematology day therapy chair is booked for the first infusion. The hematology day therapy chair needs to be booked so that treatment can start as early as possible in the day. The location of the chair, particularly for the first infusion, is an important consideration; it must be within the line of sight with resuscitation equipment readily accessible.
All medications should be charted including pre- and post-medications and medications to treat IRRs. A review of medication for the treatment schedule should be conducted by the pharmacist as per local policy/protocol. Ensure all paperwork is ready for the treatment to go ahead. Ensure that the pharmacist understands that daratumumab should not be reconstituted until they are notified on the day of infusion that the infusion will proceed. In centers that undertake nurse reconstitution of mAbs, clarification that the patient will proceed with the infusion and the required timing must be ascertained prior to reconstitution.
Education of relevant hematology oncology staff
Educate any staff who have not had previous experience using daratumumab and consider mentoring by an experienced nurse for the first infusion. Provide staff with relevant supportive information such as local unit daratumumab administration policy and guidelines, an administration checklist [Figure 1], grading and management of IRRs, and patient treatment schedules. Ensure that the staff are clear about the scheduling order if using a combination of drugs. [Figure 2], [Figure 3], [Figure 4] show the dosage regimen for daratumumab monotherapy and in combination with lenalidomide or bortezomib.
|Figure 3: Dosing schedule for daratumumab in combination with lenalidomide|
Click here to view
|Figure 4: Dosing schedule for daratumumab in combination with bortezomib.|
Click here to view
Refer to patient medical records for the latest medical/nursing patient care plan and confirm that these are consistent with treatment orders. Check that the patient has obtained the relevant post-infusion supportive medication. Carry out patient baseline observations. Notify the pharmacy and determine the time for daratumumab availability.
Blood test monitoring
Check baseline blood test results before administration of daratumumab. Monitor blood testing within a treatment cycle according to local policy.
Ensure that the patient has an orientation of the day unit and explain the schedule for the day. Discuss why the pre-medication is being used and that IRRs may occur when daratumumab is administered and ensure that any patient allergies are known and do not contraindicate planned treatment. Reassure the patient that the IRRs are generally mild and occur most frequently during the first infusion. Tell the patient what they should look out for and when to alert the nurse. Explain that a health-care professional will be monitoring the patient during the infusion. Explain that if the patient experiences an IRR, daratumumab treatment may be paused. The earlier an IRR is detected, the shorter the delay to the dose. Earlier detection may reduce the severity of the symptoms and therefore increase the likelihood that the infusion can proceed.
To prevent the occurrence of IRRs with daratumumab, the following preinfusion medications must be administered approximately 1 h and no longer than 3 h prior to every daratumumab infusion.
Dexamethasone 20 mg should be administered intravenously or an equivalent intermediate- or long-acting corticosteroid for the first two infusions, and 12 mg (oral or IV) dexamethasone thereafter in the absence of IRRs in the first two infusions.
Administer 20 mg (oral or IV) dexamethasone prior to every daratumumab infusion.
- Oral antipyretics (paracetamol 500–1000 mg)
- Oral or IV antihistamine (loratadine 10 mg or equivalent).
There is also some evidence that the use of montelukast (a leukotriene receptor antagonist) may also be effective as a preinfusion medication for IRRs.
Place a sign on the IV stand or in a visible location showing the start time for appropriate administration of daratumumab. It is important that daratumumab treatment is not started too soon after the administration of premedications as this may increase the risk of an IRR.
Administration of daratumumab
Ensure that there are clear daratumumab administration guidelines readily available [Table 4]. Daratumumab is administered as an IV infusion, through a well-functioning IV catheter using an infusion set with a flow regulator to control the infusion rate. The infusion solution must be filtered using an inline, sterile, nonpyrogenic, low protein-binding polyethersulfone filter (0.2 μm) during the infusion. If not used immediately, the diluted solution can be stored for up to 24 h at refrigerated conditions (2°C–8°C) and protected from light. Allow the solution to come to room temperature and use immediately as the daratumumab solution does not contain a preservative. The diluted solution should be used within 15 h at room temperature (15°C–25°C) and in room light. Do not infuse daratumumab concomitantly in the same IV line with other agents. Do not store any unused portion of the infusion solution for reuse.,
Following dilution, the daratumumab infusion should be intravenously administered at the appropriate infusion rate which is described below and presented in [Table 4]. Start the administration of daratumumab and document the start time. Remind the patient about potential IRRs. The median time to onset of a reaction is 1.4 h, but can occur at any time throughout the infusion. Be aware that there will be a delay before the active drug reaches the patient as it needs to flow from the infusion bag through the tubing to the cannula and patient. All attending health-care professionals should be made aware when a patient is undergoing their first infusion due to the higher risk of an IRR during the first exposure. First time patients should be kept within direct line of sight during initial infusion commencement. An increase in flow rate can also result in IRRs and so it is important that patients are also carefully observed at each increment of flow rate.
Daratumumab is to be diluted in normal saline (NS) to a total volume of 1000 mL by withdrawing a volume of NS equivalent to the volume of daratumumab to be added, prior to adding daratumumab. The infusion should be administered at an initial rate of 50 mL/h. In the absence of IRRs/hypersensitivity, the rate of the infusion can be escalated in increments of 50 mL/h every 60 min in the first 3 h to a maximum rate of 200 mL/h.
If the first infusion of daratumumab was well tolerated by the patient (absence of IRRs with severity NCI CTCAE Grade 2 or above during the first 3 h), then the second infusion will be diluted in 500 mL of NS and administered at an initial rate of 50 mL/h and increased by 50 mL/h increments at 60 min intervals, as tolerated, to a maximum rate of 200 mL/h. If the previous infusion was not well tolerated, then instructions for the first infusion should be used.
If the first two infusions of daratumumab were well tolerated by the patient (defined by an absence of IRRs with severity Grade 2 or above during a final infusion rate of ≥100 mL/h), then subsequent infusions will be diluted in 500 mL of NS and administered at an initial rate of 100 mL/h and increased by 50 mL/h increments at 60 min intervals, as tolerated, to a maximum rate of 200 mL/h. If the previous infusion was not well tolerated, then instructions for the second infusion will be used.
Hypertension and hypotension
Hypertension is common in patients with MM and hypertension can occur as an IRR. Take regular blood pressure measurements during daratumumab administration. Hypotension is less common but can also occur.
Infusion-related reaction and adverse effect management
If IRRs occur despite the implementation of premedications, it is crucial to stop the daratumumab infusion immediately, even if only mild symptoms are detected. The infusion should be stopped until symptoms have resolved. Ensure that clear IRR assessment and management guidelines are readily available.
[Table 2] and [Table 5] outline the grading and infusion administration recommendations for IRRs., (See [Appendix]) [Additional file 1] It is critical to obtain clear and accurate documentation for any IRRs, as this information will enable the clinician to decide whether rechallenge is feasible and safe. Nurses must record the time that the IRR occurred and the grade and symptoms of the reaction along with any interventions including timing and response.
|Table 5: Administration guidelines for infusion recommencement after infusion-related reactions|
Click here to view
The administration of another dose of an antihistamine can be considered; this may shorten the time to restart the infusion and may also result in faster resolution of the symptoms. Other medications can be given at the clinician's discretion, for example, non-steroidal anti-inflammatory drugs, narcotics, or IV fluids. Oxygen can also be given. It may be worthwhile to have an IRR pack readily available which holds appropriate medication to treat the reactions. Every IRR and every patient is different and it is important to be able to consult a clinician.
Once the symptoms have been resolved, the infusion may be restarted at no more than half the rate during which the IRR occurred. Document the time of symptom resolution and the time and description of infusion recommencement. There is an infusion record page at the end of this article that could be used to document key infusion aspects including IRRs. The pharmacist/prescriber must be made aware that an IRR occurred so that the next dose of daratumumab is made up appropriately.
Completion of daratumumab treatment and discharge
Document the time that the infusion was completed. If there were IRRs, document the type, grade, and management of the reaction as this will determine the delivery of the second infusion. For the first infusion, the patient should wait for 2 h after the infusion is complete to monitor for late-onset IRRs. The patient is then discharged to home or admitted to a ward with post-infusion medications. We suggest that the booked inpatient bed should not be released until it is confirmed that it is not needed at the end of the 2 h observation period.
Oral corticosteroids should be administered to prevent the occurrence of delayed IRRs:,
Patients receiving daratumumab monotherapy
- Oral corticosteroid (4 mg dexamethasone or equivalent) should be administered on each of the 2 days following all daratumumab infusions (beginning the day after the infusion).
Patients receiving combination therapy:
- Consider administering ≤4 mg dexamethasone (or equivalent) the day after daratumumab infusion. However, if a background regimen-specific corticosteroid (e.g. dexamethasone) is administered the day after the daratumumab infusion, additional post-infusion medications may not be needed.
Patients with a history of obstructive pulmonary disease require careful observation and may need additional post-infusion medication, including short- and long-acting bronchodilators and inhaled corticosteroids. These inhaled post-medications may be discontinued after the first four infusions if the patient has not experienced any major IRRs.
Patients with MM have an increased risk of developing viral infections, including herpes zoster., For patients receiving daratumumab, it is recommended that herpes zoster prophylaxis be considered for the prevention of herpes zoster virus reactivation. Antiviral prophylaxis should be initiated within 1 week after starting daratumumab and continued for 3 months following completion of treatment.
Nursing staff need to emphasize the key messages about post-infusion medications, and ensure that the patients and their family members/carers understand the possibility of delayed IRRs and know what symptoms should be reported. Re-emphasize that the patient must carry the blood type wallet card for 6 months following the completion of daratumumab therapy. Nurses should ensure that the patient has the relevant contact details, follow-up medical appointments, blood typing alert card, and any pathology forms required prior to the next infusion. Explain the subsequent dosing schedule and length of the second and subsequent infusions to the patient.
| Conclusion|| |
Daratumumab is a novel and promising medication for the treatment of patients with RR MM. Ongoing trials are also assessing its safety and efficacy in newly diagnosed patients. The risk of IRRs with daratumumab infusion is well established, and our clinical experience to date is consistent with other findings that the IRRs are largely mild in severity and are manageable. It is important that health-care professionals ensure that patients starting daratumumab are made aware of the duration and scheduling of treatment so that patient expectations can be managed. The practical guidelines outlined in this article will help nurses involved in the administration of daratumumab to improve the treatment experience of patients with MM.
The authors thank Theresa Wade, PhD of WriteSource Medical Pty Ltd, Sydney, Australia, for providing medical writing support which was funded by Janssen-Cilag Australia Ltd in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). The authors thank Andrew Spencer, Head, Malignant Hematology and Stem Cell Transplantation Service, Alfred Health and Janssen-Cilag for carrying out a medical review of the paper.
Financial support and sponsorship
Conflicts of interest
Financial support was provided by Janssen for the authors to attend an advisory board and following discussion at this meeting there was a consensus that local guidelines on the administration of daratumumab should be written. Sally Haines, Jacqueline Jagger, Kristen Houdyk and Alicia Snowden received honoraria from Janssen to attend the advisory board.
Tracy King has received honoraria from Amgen (Asia Pacific) and Janssen (India) for lecturing; Amgen, Takeda and Celgene for attendance at conference support.
Carmel Woodrow has received sponsorship from Amgen, Celgene and Janssen to attend conferences and workshops.
Jacqueline Jagger has received honoraria from Janssen and Amgen and has received travel assistance and accommodation for meetings from Celgene and Novartis.
| References|| |
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al.
Multiple myeloma. Nat Rev Dis Primers 2017;3:17046.
Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: A review about the future. J Hematol Oncol 2016;9:52.
Snowden JA, Greenfield DM, Bird JM, Boland E, Bowcock S, Fisher A, et al.
Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Br J Haematol 2017;176:888-907.
Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wäsch R, et al.
Comorbidity as a prognostic variable in multiple myeloma: Comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 2011;1:e35.
King TA, King MT, White KJ. Patient reported outcomes in optimizing myeloma patients' health-related quality of life. Semin Oncol Nurs 2017;33:299-315.
Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, et al.
Maintenance therapy with immunomodulatory drugs in multiple myeloma: A Meta-analysis and systematic review. J Natl Cancer Inst 2016;108. pii: djv342.
Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al.
Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients. Haematologica 2015;100:107-13.
Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al.
European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica 2015;100:1254-66.
Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol 2009;83:139-48.
Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, et al.
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: Results of a European, multicenter cohort study. Support Care Cancer 2014;22:417-26.
Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, et al.
Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: Results from a population-based study using the PROFILES registry. Eur J Haematol 2012;89:311-9.
Quach H, Prince HM. Clinical Practice Guideline Multiple Myeloma v4. Medical Scientific Advisory Group (MSAG) to the Myeloma Foundation of Australia (MFA); 2017.
Moreau P, van de Donk NW, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, et al.
Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma. Drugs 2016;76:853-67.
Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, et al.
DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-9.
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al.
Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. Br J Haematol 2007;138:176-85.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al.
Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N
Engl J Med 2016;375:754-66.
Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al.
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 2016;128:37-44.
Spencer A, Hungria VT, Mateos M, Nooka A, Estell J, Barreto WJ, et al.
Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated efficacy and safety analysis of castor. In: Proceedings of the 59th
Annual Meeting and Exposition American Society of Hematology. Atlanta, United Sates: 2017. p. 9-12. Available from: https://www.ash.confex.com/ash/2017/webprogram/Paper104182.html
. [Last accessed on 2018 Jan 30].
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al.
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N
Engl J Med 2016;375:1319-31.
Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Morton J, et al.
Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Updated efficacy and safety analysis of Pollux. In: Proceedings of the 59th
Annual Meeting and Exposition American Society of Hematology. Atlanta, United States; 2017. Available from: https://ash.confex.com/ash/2017/webprogram/Paper102915.html
. [Last accessed on 2018 Jan 30].
Vogel WH. Infusion reactions: Diagnosis, assessment, and management. Clin J Oncol Nurs 2010;14:E10-21.
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al.
Targeting CD38 with daratumumab monotherapy in multiple myeloma. N
Engl J Med 2015;373:1207-19.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al.
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N
Engl J Med 2018;378:518-28.
Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al.
Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015;55:1545-54.
Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, et al.
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Intern Med J 2018;48:210-20.
Maddock C, Lewis I, Ahmad K, Sullivan R. Online information needs of cancer patients and their organizations. Ecancermedicalscience 2011;5:235.
Rutten LJ, Arora NK, Bakos AD, Aziz N, Rowland J. Information needs and sources of information among cancer patients: A systematic review of research (1980-2003). Patient Educ Couns 2005;57:250-61.
Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, et al
. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Blood 2016;128:2142.
| Authors|| |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]